The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Emanuela Branchetti - H.C. Wainwright & Co., LLC - Analyst
: Good afternoon. This is Emanuela on for Joe. Thank you for taking our questions. With regards to the partnership with Nippon, and obviously they
would be responsible for the commercialization and distribution of CAP-1002 if approved. But given that experience with DMD, we were wondering
what additional influence should we expect from Nippon in the development of the asset?
Question: Emanuela Branchetti - H.C. Wainwright & Co., LLC - Analyst
: Understood. Thanks for the added -- and it's a -- regarding CAP-1002, are you considering an ex-US development as well?
Question: Emanuela Branchetti - H.C. Wainwright & Co., LLC - Analyst
: Of course, thank you for that. And I guess in the upcoming data on INSPIRE, can you help us maybe set our expectation on the results, especially
with regards to efficacy and considering CAP-1002 mechanism of action?
Question: Emanuela Branchetti - H.C. Wainwright & Co., LLC - Analyst
: Of course, and thank you for that. Yeah, looking forward to the data. And finally, for me, with the partnership for HOPE-3 secured, this is obviously
increasing your resources available for the development of the exosome platform. Can you provide more color on what are you prioritizing on that
front?
Question: Emanuela Branchetti - H.C. Wainwright & Co., LLC - Analyst
: Got it. Thank you.
| 
